Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma Co's Total Assets for the quarter that ended in Mar. 2026 was 円804,571 Mil.
During the past 12 months, Sumitomo Pharma Co's average Total Assets Growth Rate was 7.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -8.10% per year.
During the past 5 years, the average Total Assets Growth Rate was -8.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 3.50% per year.
During the past 13 years, Sumitomo Pharma Co's highest 3-Year average Total Assets Growth Rate was 28.30%. The lowest was -13.10%. And the median was 5.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sumitomo Pharma Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sumitomo Pharma Co Total Assets Related Terms
Sumitomo Pharma Co Total Assets Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sumitomo Pharma Co's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (TSE:4506) has a Total Assets of 円804,571 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Total Assets too high?
Sumitomo Pharma Co's current Total Assets is 円804,571 Mil. Overall, Sumitomo Pharma Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Total Assets compare to ZTS and UTHR?
Sumitomo Pharma Co's Total Assets of 円804,571 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Total Assets is 円804,571 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円837.87, compared to a current price of 円1,329.00 — trading 58.6% above its estimated fair value. The current Total Assets is 円804,571 Mil. Sumitomo Pharma Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Total Assets is 円804,571 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of 円1,329.00 is trading 58.6% above its estimated GF Value™ of 円837.87.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for TSE:4506:
Total Assets: 円804,571 Mil
GF Value™: 円837.87 vs. price of 円1,329.00 (58.6% above fair value)
No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for TSE:4506
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4506 has been successfully added to your 
